Burning Rock Dx(US:BNR) Jin Rong Jie·2025-12-16 15:19Core Viewpoint - The article highlights the performance and growth of Burning Rock Biotech (BNR), emphasizing its focus on precision oncology through next-generation sequencing (NGS) technology and its significant financial results for the upcoming fiscal year [1]. Financial Performance - As of September 30, 2025, Burning Rock's total revenue is projected to be 413 million RMB, representing a year-on-year growth of 6.02% [1]. - The company's net profit attributable to shareholders is expected to be -39.96 million RMB, showing a substantial year-on-year increase of 84.94% [1]. Company Overview - Burning Rock Biotech was established in 2014 with a mission to "guard the light of life with science," focusing on clinically valuable NGS for precision oncology [1]. - The company holds a leading market share in tumor patient testing in China and collaborates with global oncology pharmaceutical companies on biomarkers and companion diagnostics [1]. - The company has made significant strides in early cancer detection across multiple cancer types [1]. Regulatory Milestones - In July 2018, Burning Rock received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [1]. - The laboratory in Guangzhou has been certified by the Guangdong Provincial Clinical Testing Center for high-throughput sequencing and has obtained CLIA and CAP laboratory quality system certifications in both China and the United States [1]. Future Directions - The company aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [1].